Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
about
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studiesβ-Cell glutamate signaling: Its role in incretin-induced insulin secretionIncretin physiology and pathophysiology from an Asian perspectiveNon-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?Lipotoxicity disrupts incretin-regulated human β cell connectivityEfficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.The potential role of incretin therapy in the hospital setting.JNK3 is required for the cytoprotective effect of exendin 4Postprandial oxidative stress and gastrointestinal hormones: is there a link?Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies.The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.Adaptation of β-Cell and Endothelial Function to Carbohydrate Loading: Influence of Insulin ResistanceGlutamate acts as a key signal linking glucose metabolism to incretin/cAMP action to amplify insulin secretion.Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin.Third Exposure to a Reduced Carbohydrate Meal Lowers Evening Postprandial Insulin and GIP Responses and HOMA-IR Estimate of Insulin Resistance.N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptorCoadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemiaThe incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion.What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters.On the potential of acarbose to reduce cardiovascular disease.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.Human biology of taste.Minireview: intraislet regulation of insulin secretion in humans.DPP-4 inhibitors: pharmacological differences and their clinical implications.The role of glucagon on type 2 diabetes at a glance.Molecular Pharmacology of the Incretin Receptors.Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice.Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.Feedback inhibition of CREB signaling promotes beta cell dysfunction in insulin resistance.New Approaches to Feline Diabetes Mellitus: Glucagon-like peptide-1 analogs.
P2860
Q24288949-BC52F4C6-8EA2-4106-A910-F6FB454744EDQ26749202-FCA2AB86-5750-41D1-A182-1F0EFDE3E0F8Q26784623-D40A2BA4-9C23-44FC-A3F3-764570F4366BQ27006992-3E1915F4-74D7-4688-8B32-BD706729799AQ30634760-FC0CD976-C0F4-47B0-8AD9-AB6591C06449Q31082841-D4D340E6-3CDC-4A4E-A278-27FEAE95957BQ33792390-AC915D1A-8EBE-41CA-9BEB-6D05399EDDCFQ33852246-8EABDEA0-3B0E-4420-AF2F-1E6C869F83F6Q34070530-75B10EFB-BFCE-429F-9B72-811AD92B2140Q34503601-1AFBCE96-BB57-429A-8998-AA1F7F439D11Q34996877-F89BE0CB-57EF-4830-991A-3467E7338B8BQ35239483-5EA9A8BB-F9AF-4877-84C3-E04AAD89F1D3Q35769553-194BAB8A-93C5-43C2-99B5-BC5D8A8B1E89Q35952701-969FFE87-0D4C-4D25-81B3-B17E6702A247Q35975651-539B9B05-79B9-4FAC-B9B3-FDB2518FE864Q36178550-E87CBF02-E6E6-4A74-987C-F0B72A78FADFQ36599662-864E7BC2-27B7-4B50-88AC-B58B68CC32CAQ36720596-9BFAA0D6-E2FC-46AE-B32B-470DFD160512Q36902183-13A6D956-1F2C-4291-BF49-CAD3550EF44DQ36924521-B50957A7-5CC9-43A8-9400-7622AB42C76AQ37412811-C0493247-F595-46CC-9879-3F5AFC9304FBQ37717838-342A8589-8E37-4910-8FB7-84F8D9D6CFA8Q38014516-921F2BD7-9D7D-4665-8863-24A3B303A8E4Q38017726-9C28E1A5-334E-4A06-8D05-8D892A6302D5Q38078816-AA54466B-0E6F-4CAC-9286-2B11D13351C7Q38101677-5B4BC6C0-B107-4729-BF17-673F57F3340CQ38116398-88C48BD6-B85E-463F-B315-B85689C75A3BQ38163482-C9A3C5CB-3EDD-4AD2-8856-DCE313B787E6Q38244576-AE5A3C21-8261-4B04-83F3-D1D369262CA4Q38245233-BB9AF30B-C666-4B11-A7C5-E2A95B4A2234Q38537930-89575780-0AF7-40BA-8FD8-D32EC1FDD5A4Q38563239-EBD94B3B-70B0-4D0E-BC5C-28AD1E0180F1Q38587097-5F416292-EC21-42EC-AB3E-8F026F83BDE9Q38602769-04642905-27CD-4393-8FD8-919957B89AFDQ38616170-EC19446C-2CB0-4684-A064-0BC754504725Q38690867-55202457-C2B3-43B8-BECD-57DF2706DA1FQ38724829-EEFC9800-27DB-4158-9A74-2F3A8DE83767Q38864019-153B1D7B-9C17-4FC0-9CCB-A711F7BC6E2BQ38907059-CAFC609A-C82C-4165-9032-2228253D02C2Q38937626-10472E69-A29F-4A9B-BD5E-53E1EE27ADB4
P2860
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Loss of incretin effect is a s ...... acteristic of type 2 diabetes.
@en
type
label
Loss of incretin effect is a s ...... acteristic of type 2 diabetes.
@en
prefLabel
Loss of incretin effect is a s ...... acteristic of type 2 diabetes.
@en
P2860
P50
P921
P356
P1433
P1476
Loss of incretin effect is a s ...... acteristic of type 2 diabetes.
@en
P2093
Filip K Knop
Thure Krarup
P2860
P304
P356
10.2337/DC11-S227
P407
P478
34 Suppl 2
P5008
P577
2011-05-01T00:00:00Z